Loading
Companies would put their cancer drugs into a shared licensing pool so that any qualified investigator can test combinations of drugs from different owners under one standard agreement, with royalties split by a fixed formula.
A voluntary pool, administered by a neutral body on the model of the Medicines Patent Pool and the MPEG patent pools, in which participating companies grant a standard non-exclusive licence for their approved and late-stage oncology agents to be used in combination trials sponsored by academic groups, non-profits or other pool members, with pre-agreed terms for drug supply, data rights, publication and downstream royalty sharing if a combination is approved. Today each combination requires a bespoke negotiation that can take longer than the trial; pooled terms cut that to weeks. Regulators would recognise pool trials as acceptable for combination labelling.
Shares A permanent neutral non-profit sponsor for multi-company platform trials, Radiotherapy + immunotherapy, Secrecy and intellectual property block collaboration, Too many combinations to test.
Shares A regulator-endorsed standard contract for inter-company combination trials, Secrecy and intellectual property block collaboration.
Shares An antitrust safe harbour for cross-company combination trials and data pooling, Secrecy and intellectual property block collaboration.
Shares A permanent neutral non-profit sponsor for multi-company platform trials, Secrecy and intellectual property block collaboration.
Shares An antitrust safe harbour for cross-company combination trials and data pooling, Secrecy and intellectual property block collaboration.
Shares Secrecy and intellectual property block collaboration, Too many combinations to test.
Shares Secrecy and intellectual property block collaboration, Too many combinations to test.
Shares Secrecy and intellectual property block collaboration, Too many combinations to test.